Document is current
Any future updates will be listed below
-
Authors
Zoeller, Jason J.
Vagodny, Aleksandr
Daniels, Veerle W.
Taneja, Krishan
Tan, Benjamin Y.
DeRose, Yoko S.
Fujita, Maihi
Welm, Alana L.
Letai, Anthony
Leverson, Joel D.
Blot, Vincent
Bronson, Roderick T.
Dillon, Deborah A.
Brugge, Joan S. https://orcid.org/0000-0002-2547-4814
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-12-1-0077, W81XWH-16-1-0340, W81XWH-16-1-0340)
- License Information
-
More Information
Article History
Received: 30 June 2020
Accepted: 16 November 2020
First Online: 30 November 2020
Ethics approval and consent to participate
: Studies involving mouse models were completed in accordance with IACUC#0990 and Harvard University ARCM policies. Studies involving human tumors were previously collected via DFCI IRB#93085 and were de-identified prior to analysis.
: Not applicable.
: J.J. Zoeller: none. A. Vagodny: none. V.W. Daniels: none. K. Taneja: none. B.Y. Tan: none. Y.S. DeRose: co-inventor of the HCI PDX models (licensing to for-profit entities is controlled by the University of Utah, not by the inventors). M. Fujita: co-inventor of the HCI PDX models. A.L. Welm: SAB Oncolexis; unrelated contract research Aslan, Zeno; co-inventor of the HCI PDX models. A. Letai: research support AbbVie, Novartis; SAB Dialectics Therapeutics; Founder & SAB Flash Therapeutics, Zeno, Vivid Bioscience. J.D. Leverson and V. Blot are employees and shareholders of AbbVie. R.T. Bronson: none. D.A. Dillon: consulting fees Novartis; Oncology Analytics, Inc. J.S. Brugge: unrelated sponsored research Roche Pharmaceuticals.
